Category Archives: Multaq

Featured Stories

U.K. Regulators Issue Additional Guidance for Metal-on-Metal Hip Implant Recipients

Regulators in the U.K. are once again issuing advice to doctors and other healthcare professionals involved in the follow-up of patients with metal-on-metal hip replacement devices. In an alert issued by the Medicines and Healthcare products Regulatory Agency (MHRA), guidance is provided for four groups of metal-on-metal hip implant ...

Read More

Three Injured, Long Island Railroad Train Hits Car on Tracks

Three Injured When Long Island Railroad Train Hits Car on Tracks

Three people, including a train engineer, were injured on Wednesday when a Long Island Rail Road train hit a livery cab on the tracks west of Wyandanch station, LIRR officials said. LIRR spokesman Salvatore Arena said the driver of the Lincoln Town Car was taken to Good Samaritan Hospital Medical Center ...

Read More

1,000+ Australians Join DePuy ASR Hip Implant Class Action Lawsuit

A class action lawsuit filed in Australia over DePuy Orthopaedics’ recalled metal-on-metal ASR Hip Implants has signed up more than 1,000 plaintiffs. The attorneys representing the Australian ASR Hip Implant lawsuit plaintiffs recently told The Courier-Mail that damages in the lawsuit are expected to be worth more than $200 million. One ...

Read More

Estate of Kentucky Man Alleges Wrongful Death Due to Actos Bladder Cancer

National law firm, Parker Waichman LLP, just filed a lawsuit on behalf of the estate of a Kentucky man who developed bladder cancer and subsequently died, allegedly due to the use of diabetes drug, Actos. The lawsuit names Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceuticals North America, ...

Read More

DePuy ASR Hip Implants, Other Faulty Medical Devices Subject to Little FDA Oversight, Investigation Finds

A newly-published investigation from ProPublica has revealed that several questionable types of medical devices, including DePuy Orthopaedic’s recalled ASR hip implant, managed to make it to market without much scrutiny on the part of the U.S. Food & Drug Administration (FDA).

Read More

Parker Waichman Representing Another Louisiana Plaintiff in Actos Bladder Cancer Lawsuit

A Louisiana man has become the latest to claim that his taking the type 2 diabetes drug Actos resulted in developing bladder cancer. He has filed a lawsuit against the Japanese manufacturer of the drug and the marketer of it in the U.S., claiming they failed to warn about this ...

Read More

West Virginia Man Claims Metal-on-Metal DePuy Pinnacle Hip Replacement Led to Pain, Elevated Cobalt Levels

A West Virginia man fitted with a metal-on-metal version of DePuy Orthopaedics’ Pinnacle Hip Implant System has filed suit against the company and its parent, Johnson & Johnson, alleging the device caused him to suffer pain and elevated cobalt levels. The Plaintiff is being represented by the national law ...

Read More

EMA Seeks Stronger Pradaxa Guidance for Bleeding Side Effects

Regulators in Europe have again asked Boehringer Ingelheim, the manufacturer of the blood thinner Pradaxa, to update the drug’s label with additional information regarding Pradaxa bleeding side effects. According to the European Medicines Agency (EMA), the new guidance should include more specific information on when Pradaxa must not be used, ...

Read More

Crash on N.State Pkwy Kills Port Jefferson Station Man

Single-Car Crash on Northern State Parkway Kills Port Jefferson Station Man

81-year-old Port Jefferson Station man was killed in a crash at 4:57 a.m.. He lost control of the vehicle traveling west on Northern State Pkwy, on exit 42, Dix Hills.

Read More

Middle-aged Dronedarone Users Have Higher Risk of Hospitalization

Middle-aged Dronedarone Users Have Higher Risk

New study results reveal that patients age 61 and younger treated with the heart rhythm drug dronedarone (Multaq) have a higher risk for hospitalization than those with treated other anti-arrhythmic drugs. The study, published in Circulation: Cardiovascular Quality and Outcomes, … Continue reading

Posted in Health Concerns, Multaq, Pharmaceuticals | Tagged , , , , |

Multaq Patients Had Double Death Risk in Halted Trial

A study has found that patients taking < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq to control serious, permanent atrial fibrillation, may face a doubled risk of death. Such Multaq patients also face a much higher risk of suffering a heart attack and stroke, according to … Continue reading

Posted in Multaq, Pharmaceuticals |

Multaq Side Effect Concerns Prompt Restrictions in Europe

Use of < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq, the Sanofi-Aventis heart drug that has been linked to heart, liver and lung problems, has been restricted by regulators in Europe. According to a report from The Wall Street Journal, a committee of the European Medicines … Continue reading

Posted in Multaq, Pharmaceuticals |

Multaq Faces FDA Scrutiny As Safety Concerns Mount

The U.S. Food & Drug Administration (FDA) said yesterday that it is continuing to review the safety of < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq, as more and more specialists report they are no longer prescribing the drug. Multaq has been linked to a number … Continue reading

Posted in Multaq, Pharmaceuticals |

Multaq Maker Issues Formal Alert for Halted Study

Sanofi-Aventis has formally alerted doctors that a clinical trial involving < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone) was halted because patients in the study’s Multaq group were dying at more than twice the rate of that of patients taking placebo. “Healthcare professionals are advised … Continue reading

Posted in Multaq, Pharmaceuticals |

Canada Reviewing Multaq Over Heart Worries

Add Canada to the list of countries taking a deeper look into prescription medication, < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone). Health Canada, said CTV News, is reviewing the drug’s safety. Multaq is already approved to treat temporary Atrial Fibrillation (AF), or abnormal heart … Continue reading

Posted in Multaq |

New Multaq Alert Issued by FDA

Following an expanded European Medicines Agency (EMA) probe, the U.S. Food and Drug Administration (FDA), as expected, announced that it will be reviewing information from a < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq clinical trial that was stopped over higher-than-expected adverse heart reactions in trial … Continue reading

Posted in Multaq |

Multaq Heart Side Effects Under Review in Europe

Sanofi is facing an expansion of an ongoing review of its atrial fibrillation (AF) treatment, < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone). The European Medicines Agency (EMA) found that a study revealed possible heart risks in patients using the drug, said FiercePharma. The Agency … Continue reading

Posted in Multaq, Pharmaceuticals |

Multaq Trial Halted Due to Significant Increase in Heart Problems

A clinical trial for < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (dronedarone) has ended early after a significant number of heart-related side effects were seen in the study. The trial, known as the PALLAS study, was testing Multaq’s as a treatment for permanent atrial fibrillation. … Continue reading

Posted in Multaq, Pharmaceuticals |

Multaq Patients Should Undergo Liver Function Tests

European regulators recently warned that < "http://www.yourlawyer.com/topics/overview/multaq-dronedarone-liver-damage-failure-lawsuit-lawyer-attorney">Multaq (donedarone) could put patients at risk for severe liver injuries. The European Medicines Agency (EMA) is now recommending that doctors perform liver function tests before treating atrial fibrillation patients with Multaq. The European … Continue reading

Posted in Multaq, Pharmaceuticals | Tagged , , , , |

© 2005-2018 Parker Waichman LLP ®. All Rights Reserved.